<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4457</td>
<td>Selected Articles from This Issue</td>
<td></td>
</tr>
<tr>
<td>4459</td>
<td>Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates</td>
<td>Honey K. Oberoi and Elena Garralda</td>
</tr>
<tr>
<td>4462</td>
<td>TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?</td>
<td>Riccardo Bomben, Antonella Zucchetto, Massimo Gentile, and Valter Gathei</td>
</tr>
<tr>
<td>4462</td>
<td>Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia</td>
<td>Clive S. Zent</td>
</tr>
<tr>
<td>4468</td>
<td>Facts and Hopes in Multiple Myeloma Immunotherapy</td>
<td>Adam S. Sperling and Kenneth C. Anderson</td>
</tr>
<tr>
<td>4469</td>
<td>Vorosidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial</td>
<td>Ingo K. Mellinghoff, Marta Penas-Prado, Katherine B. Peters, Howard A. Burris III, Elizabeth A. Maher, Filip Janku, Gregory M. Cote, Macarena I. de la Fuente, Jennifer L. Clarke, Benjamin M. Ellingon, Saewon Chun, Robert J. Young, Hua Liu, Sung Choe, Min Lu, Kha Le, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, and Patrick Y. Wen</td>
</tr>
<tr>
<td>4500</td>
<td>A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes</td>
<td>David A. Potter, Alexandra Thomas, and Hope S. Rugo</td>
</tr>
</tbody>
</table>

**HIGHLIGHTS**

**SPECIAL FEATURES**

**CCR Translations**

**CLINICAL TRIALS: TARGETED THERAPY**
TABLE OF CONTENTS

4521 Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Javier Garcia-Corbacho, Valentina Boni, Mark Stroh, Alison L. Hannah, Song Wang, Henry Castro, and Alexander Spira
See related commentary, p. 4459

4531 Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib
Christian Briegel, Kathrine Aarup, Mathias H. Torp, Michael A. Andersen, Christina W. Yde, Xin Tian, Adrian Wiestner, Inhye E. Ahn, and Carsten U. Niemann
See related commentary, p. 4462

4539 Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
Matthew R. Smith, Shibui Thomas, Michael Gormley, Simon Chowdhury, David Olmos, Stéphane Oudard, Felix Y. Feng, Yashoda Rapiurohit, Karen Urtishak, Deborah Ricci, Brendan Rooney, Angela Lopez-Gitlitz, Margaret Yu, Alexander W. Wyatt, Mark Li, Gerhardt Attard, and Eric J. Small

4549 Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer

CLINICAL TRIALS: IMMUNOTHERAPY

4557 Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

4566 A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer

4574 Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

PRECISION MEDICINE AND IMAGING

4587 Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer

4599 Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer
**TRANSLATIONAL CANCER MECHANISMS AND THERAPY**

**4610** Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition

**4624** Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Maria Joao Baptista, Sivasubramanian Baskar, Erika M. Gaglione, Keyvan Keyvanfar, Inhye E. Ahn, Adrian Wiestner, and Clare Sun
See related commentary, p. 4465

**4634** Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
Munawar Anwar, Qi Tong Chen, Dengjie Ouyang, Shouman Wang, Ning Xie, Quang Ouyang, Peizi Fan, Liyuan Qian, Gannong Chen, Enxiang Zhou, Lei Guo, Xiaowen Gu, Boning Ding, Xiaohong Yang, Liping Liu, Chao Deng, Zhi Xiao, Jing Li, Yunqi Wang, Shan Zeng, Jinhui Hu, Wei Zhou, Bo Qiu, Zhongming Wang, Jie Weng, Mingwen Liu, Yi Li, Tiegang Tang, Jianguo Wang, Hui Zhang, Bin Dai, Wuping Tang, Tao Wu, Maoliang Xiao, Xiantao Li, Hailong Liu, Lai Li, and Wenjun Yi

**CORRECTION**

**4664** Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes, Nadia Arang, Manuela Tiago, Silvia Coma, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, and J. Silvio Gutkind

AC AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows a section of a pretherapeutic tumor sample from a patient with metastatic melanoma. Immunohistochemical staining shows T- and B-lymphocyte interactions in the stroma compartment by dual CD3/CD19 staining. Connected bands represent spatial proximity distribution. For details, see the article by Brase and colleagues on page 4500 of this issue.